Therapeutic targeting of the angiopoietin-TIE pathway - PubMed (original) (raw)
Review
. 2017 Sep;16(9):635-661.
doi: 10.1038/nrd.2016.278. Epub 2017 May 19.
Affiliations
- PMID: 28529319
- DOI: 10.1038/nrd.2016.278
Review
Therapeutic targeting of the angiopoietin-TIE pathway
Pipsa Saharinen et al. Nat Rev Drug Discov. 2017 Sep.
Abstract
The endothelial angiopoietin (ANG)-TIE growth factor receptor pathway regulates vascular permeability and pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. Drugs that target the ANG-TIE pathway are in clinical development for oncological and ophthalmological applications. The aim is to complement current vascular endothelial growth factor (VEGF)-based anti-angiogenic therapies in cancer, wet age-related macular degeneration and macular oedema. The unique function of the ANG-TIE pathway in vascular stabilization also renders this pathway an attractive target in sepsis, organ transplantation, atherosclerosis and vascular complications of diabetes. This Review covers key aspects of the function of the ANG-TIE pathway in vascular disease and describes the recent development of novel therapeutics that target this pathway.
Similar articles
- How do angiopoietins Tie in with vascular endothelial growth factors?
Saharinen P, Bry M, Alitalo K. Saharinen P, et al. Curr Opin Hematol. 2010 May;17(3):198-205. doi: 10.1097/MOH.0b013e3283386673. Curr Opin Hematol. 2010. PMID: 20375888 Review. - VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.
Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. Saharinen P, et al. Trends Mol Med. 2011 Jul;17(7):347-62. doi: 10.1016/j.molmed.2011.01.015. Epub 2011 Apr 12. Trends Mol Med. 2011. PMID: 21481637 Review. - Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
Parmar D, Apte M. Parmar D, et al. Eur J Pharmacol. 2021 May 15;899:174021. doi: 10.1016/j.ejphar.2021.174021. Epub 2021 Mar 16. Eur J Pharmacol. 2021. PMID: 33741382 Review. - Insight into the Role of Angiopoietins in Ageing-Associated Diseases.
Hayashi SI, Rakugi H, Morishita R. Hayashi SI, et al. Cells. 2020 Dec 8;9(12):2636. doi: 10.3390/cells9122636. Cells. 2020. PMID: 33302426 Free PMC article. Review. - Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.
Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Khan M, et al. Cells. 2020 Aug 10;9(8):1869. doi: 10.3390/cells9081869. Cells. 2020. PMID: 32785136 Free PMC article. Review.
Cited by
- Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab.
Todoroki T, Takeuchi J, Ota H, Nakano Y, Sajiki AF, Nakamura K, Kaneko H, Nishiguchi KM. Todoroki T, et al. Invest Ophthalmol Vis Sci. 2024 Sep 3;65(11):15. doi: 10.1167/iovs.65.11.15. Invest Ophthalmol Vis Sci. 2024. PMID: 39250120 Free PMC article. - Fluid bolus increases plasma hyaluronan concentration compared to follow-up strategy without a bolus in oliguric intensive care unit patients.
Serlo M, Inkinen N, Lakkisto P, Valkonen M, Pulkkinen A, Selander T, Pettilä V, Vaara ST. Serlo M, et al. Sci Rep. 2024 Sep 6;14(1):20808. doi: 10.1038/s41598-024-71670-2. Sci Rep. 2024. PMID: 39242877 Free PMC article. Clinical Trial. - Changes in Ocular Blood Flow After Intravitreal Injection for Diabetic Macular Edema Between Aflibercept and Faricimab.
Mizukami T, Mizumoto S, Ishibashi T, Ueno S, Toyonishi T, Tachibana K, Mishima S, Shimomura Y. Mizukami T, et al. Clin Ophthalmol. 2024 Aug 27;18:2407-2416. doi: 10.2147/OPTH.S476307. eCollection 2024. Clin Ophthalmol. 2024. PMID: 39221078 Free PMC article. - Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists.
Downey L, Sivaprasad S, Chhabra R, Bailey C, Chakrabarti S, Elsherbiny S, Patel J, Silvestri G, Watson SL, Williams G, Parker A, Khokhar S, Lotery A. Downey L, et al. Eye (Lond). 2024 Aug 30. doi: 10.1038/s41433-024-03223-w. Online ahead of print. Eye (Lond). 2024. PMID: 39215141 - Pathophysiology in Brain Arteriovenous Malformations: Focus on Endothelial Dysfunctions and Endothelial-to-Mesenchymal Transition.
Jeong JY, Bafor AE, Freeman BH, Chen PR, Park ES, Kim E. Jeong JY, et al. Biomedicines. 2024 Aug 7;12(8):1795. doi: 10.3390/biomedicines12081795. Biomedicines. 2024. PMID: 39200259 Free PMC article. Review.
References
- Cardiovasc Res. 2009 Jul 1;83(1):24-33 - PubMed
- J Clin Oncol. 2015 Oct 20;33(30):3431-8 - PubMed
- Cancer Cell. 2010 Aug 9;18(2):171-84 - PubMed
- J Neurosci Res. 2010 Apr;88(5):1052-63 - PubMed
- Nephrol Dial Transplant. 2007 Feb;22(2):396-408 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous